ClinicalTrials.gg
CompletedNCT00258713SPIRITUpdated Sep 29, 2008

A 36-Week Extension to Protocol ISA04-03

A Phase 3 interventional study of voclosporin in Psoriasis, sponsored by Aurinia Pharmaceuticals Inc.. Completed at 29 sites in Canada. Open to participants aged 18 Years to 66 Years. Per ClinicalTrials.gov, last updated 2008-09-29.

Sponsored by Aurinia Pharmaceuticals Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
309
Allocation
Randomized
Ages
18 Years to 66 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 303 studies in Psoriasis with a site in Canada — 15 open to participants now, 32 under way, 14 of them phase 3. Psoriasis · Canada.

Enrollment
114th of 272
309 · median 227
Started
2005
with 9 others
Phase 3
139 of 303
4 open now
Registered
11th of 303
by date

Among the 303 studies in Psoriasis with a site in Canada, this one is the 114th largest by enrollment of the 272 interventional ones that give a count, is one of 10 that started in 2005, is one of 139 in phase 3, and was the 11th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

15 of the 303 studies in Psoriasis with a site in Canada are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 66 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 303 studies in Psoriasis with a site in Canada, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety and efficacy of voclosporin in patients with plaque psoriasis.

Read the detailed description

Psoriasis is a chronic skin condition that can have a significant impact on patient's physical and mental well being. The most common form of psoriasis is plaque psoriasis. Targeted treatments in psoriasis have been reported recently, yet cyclosporine, a calcineurin inhibitor (CNi) remains one of the treatments which has the greatest efficacy. Voclosporin represents the possibility of a calcineurin inhibitor which is not only as efficacious as cyclosporine A, but also has an improved toxicity profile.

03

Conditions studied

  • Psoriasis

Keywords

  • Randomized Controlled Trials
  • Immunosuppression
  • Adult
  • Chronic Disease
  • Dermatologic Agents
  • Female
  • Humans
  • Male
  • Middle Aged
  • Severity of Illness Index
  • Treatment Outcome
  • Quality of Life
  • Double-Blind Method
04

Who can participate

Ages eligible
18 Years to 66 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females aged 18-66 years inclusive at the time of visit 1.
  • Diagnosed with plaque psoriasis ≥ 6 months.
  • Currently participating in study ISA04-03 and completed the study up to and including Visit 9 of study ISA04-03.
  • Not pregnant or nursing of planning to become pregnant during the course of the study
  • Sexually-active women of (including those who are \< 1 year ) and sexually-active men who are practicing a highly effective method of . A highly effective method of birth control is defined as one that results in a low failure rate (i.e., less than 1% per year) when used consistently and correctly and will include implants, injectables, combined oral contraceptives, double-barrier method, sexual abstinence, or a sterile partner. Sexually-active men and women of child-bearing potential should continue to practice contraception as outlined above during treatment and for ≥ 3 months after the last dose of voclosporin.
  • Written prior to any study related procedures.
  • Able to keep study appointments and cooperate with all study requirements, in the opinion of the investigator.

Exclusion criteria

Exclusion Criteria:

  • Has generalized erythrodermic, guttate, or pustular psoriasis.
  • Have other dermatoses that would interfere with the evaluation of psoriasis, at the discretion of the investigator.
  • A current or history of malignancy within 5 years or a history of lymphoma at any time. Subjects can be enrolled with a history of squamous or basal cell carcinoma that has been surgically excised or removed with curettage and electrodesiccation.
  • Has current, uncontrolled bacterial, viral, or fungal infection that requires intravenous antibiotics or antifungals.
  • Has a current streptococcal infection that required oral antibiotics.
  • A known history of tuberculosis.
  • Serologic evidence or known latent (HIV), (HBV) or (HCV) virus.
  • Uncontrolled hypertension as defined as 3 readings of systolic blood pressure ≥ 150 mm Hg or diastolic blood pressure ≥ 90 mm Hg.
  • GFR ≤ 60 mL/min.
  • Unstable renal function (variation in GFR ≥ 30%).
  • , aspartate transaminase, or gamma-glutamyl transferase ≥ 3x (ULN).
  • White blood cell count ≤ 2.8x10 to the ninth power/L.
  • Triglycerides ≥ 3x ULN.
  • Is currently taking or requires the following prohibited medications or treatments during the treatment period: drugs potentiating the nephrotoxicity of voclosporin such as chronic NSAID's or ACE inhibitors, drugs interfering with it's pharmacokinetics; drugs considered to contribute to psoriasis flare; or, systemic and topical psoriasis medication (including psoralen/ultraviolet A light treatment) that may interfere with assessment of study drug efficacy.
  • Has taken biological agent(s), except flu shots, tetanus shots, or boosters, within 3 months of the start of treatment. Biological agents include any virus, therapeutic serum, toxin, antitoxin, or analogous product applicable to the prevention, treatment, or cure of diseases or injuries of man.
  • A history of clinically defined allergy to cyclosporine or any of the constituents of the voclosporin formulation (vitamin E, medium chain triglyceride oil, Tween 40, ethanol).
  • A history of alcoholism or drug addiction within 1 year prior to study entry.
  • Weighs \< 45 kg (99 lbs) or > 140 kg (308 lbs).
  • A history of disease, including mental/emotional disorder that would interfere with the subject's participation in the study, or that might cause the administration of ISA247 to pose a significant risk to the subject, in the opinion of the investigator.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
309 participants (actual)

Study arms

  • Active comparator
    1

    Drug: voclosporin

  • Active comparator
    2

    Drug: voclosporin

  • Active comparator
    3

    Drug: voclosporin

Interventions

06

What researchers measure

Primary outcomes

  1. To investigate long-term safety and tolerability of voclosporin

    Time frame: Sixty weeks of continuous treatment

Secondary outcomes

  1. To determine the proportion of subjects achieving and/or maintaining a PASI-75

    Time frame: Sixty weeks of continuous treatment

  2. To determine the proportion of subjects achieving and/or maintaining a reduction of 2 points in the SGA

    Time frame: Sixty weeks of continuous treatment

  3. To evaluate the effect of voclosporin on subject quality of life

    Time frame: Sixty weeks of continuous treatment

07

Study locations

29 sites
  • Isotechnika Investigational Site
    Calgary, Alberta T2S 3B3, Canada
  • Isotechnika Investigational Site
    Edmonton, Alberta T5J 3S9, Canada
  • Isotechnika Investigational Site
    Vancouver, British Columbia V5Z 3Y1, Canada
  • Isotechnika Investigational Site
    Vancouver, British Columbia V5Z 4E8, Canada
  • Isotechnika Investigational Site
    Winnipeg, Manitoba R3C 0N2, Canada
  • Isotechnika Investigational Site
    Moncton, New Brunswick E1C 8X3, Canada
  • Isotechnika Investigational Site
    St. John's, Newfoundland and Labrador A1B 3E1, Canada
  • Isotechnika Investigational Site
    St. John's, Newfoundland and Labrador A1B 4F8, Canada
  • Isotechnika Investigational Site
    Halifax, Nova Scotia B3H 1Z4, Canada
  • Isotechnika Investigational Site
    Barrie, Ontario L4M 6L2, Canada
  • Isotechnika Investigational Site
    Hamilton, Ontario L8N 1V6, Canada
  • Isotechnika Investigational Site
    London, Ontario N5X 2P1, Canada
  • Isotechnika Investigational Site
    London, Ontario N6A 3H7, Canada
  • Isotechnika Investigational Site
    Maple, Ontario L4K 5V2, Canada
  • Isotechnika Investigational Site
    Markham, Ontario L3P 1A8, Canada
  • Isotechnika Investigational Site
    Newmarket, Ontario L3Y 6P5, Canada
  • Isotechnika Investigational Site
    North Bay, Ontario P1B 3Z7, Canada
  • Isotechnika Investigational Site
    Oakville, Ontario L6K 1E1, Canada
  • Isotechnika Investigational Site
    Oshawa, Ontario L1H 1B9, Canada
  • Isotechnika Investigational Site
    Waterloo, Ontario N2J 1C4, Canada
  • Isotechnika Investigational Site
    Windsor, Ontario N8W 1E6, Canada
  • Isotechnika Investigational Site
    Windsor, Ontario N8W 5L7, Canada
  • Isotechnika Investigational Site
    Laval, Quebec H7G 2C6, Canada
  • Isotechnika Investigational Site
    Montreal, Quebec H2K 4L5, Canada
  • Isotechnika Investigational Site
    Montreal, Quebec H3G 1C6, Canada
  • Isotechnika Investigational Site
    Montreal, Quebec H3H 1V4, Canada
  • Isotechnika Investigational Site
    Pointe Claire, Quebec H9R 4S3, Canada
  • Isotechnika Investigational Site
    Saint Foy, Quebec G1V 4X7, Canada
  • Isotechnika Investigational Site
    Sherbrooke, Quebec J1J 2B8, Canada
08

References and documents

Publications

  • Gregory CR, Kyles AE, Bernsteen L, Wagner GS, Tarantal AF, Christe KL, Brignolo L, Spinner A, Griffey SM, Paniagua RT, Hubble RW, Borie DC, Morris RE. Compared with cyclosporine, ISATX247 significantly prolongs renal-allograft survival in a nonhuman primate model. Transplantation. 2004 Sep 15;78(5):681-5. doi: 10.1097/01.tp.0000131950.75697.71. PubMed 15371668 ↗
  • Stalder M, Birsan T, Hubble RW, Paniagua RT, Morris RE. In vivo evaluation of the novel calcineurin inhibitor ISATX247 in non-human primates. J Heart Lung Transplant. 2003 Dec;22(12):1343-52. doi: 10.1016/s1053-2498(03)00033-0. PubMed 14672749 ↗
  • Abel MD, Aspeslet LJ, Freitag DG, Naicker S, Trepanier DJ, Kneteman NM, Foster RT, Yatscoff RW. ISATX247: a novel calcineurin inhibitor. J Heart Lung Transplant. 2001 Feb;20(2):161. doi: 10.1016/s1053-2498(00)00290-4. No abstract available. PubMed 11250240 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2005, a primary completion of Jul 2006 and a completion of Jul 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2005
First posted
Nov 28, 2005
Start
Sep 2005
Primary completionActual
Jul 2006
CompletionActual
Jul 2006
Last update
Sep 29, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00258713
Lead sponsor
Aurinia Pharmaceuticals Inc.
First posted
Nov 28, 2005
Start date
Sep 2005
Primary completion
Jul 2006
Completion
Jul 2006
Last update
Sep 29, 2008

Study contacts

Robert Bissonnette, MD
principal investigator · Innovaderm Research
Richard Langley, MD, FRCPC
principal investigator · Eastern Canada Cutaneous Research Associates Ltd.
Gilles Lauzon, PhD MD FRCPC
principal investigator · University of Alberta
Kim Papp, MD, PhD
principal investigator · Probity Medical Research
Neil Shear, MD
principal investigator · Ventana Clinical Research Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Voclosporin

Start the discussion